News

Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda that takes…
Read More...

AstraZeneca’s Tagrisso (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm)…
Read More...

Pfizer Inc. announced that it is voluntarily withdrawing all lots of OXBRYTA (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is…
Read More...

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced a new strategic…
Read More...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's…
Read More...

Vanda Pharmaceuticals Inc. (Vanda) provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve…
Read More...

Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease,…
Read More...

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination…
Read More...

BeiGene, Ltd. announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA (tislelizumab) as monotherapy for the treatment of adult patients with unresectable or…
Read More...

Valneva SE, a specialty vaccine company, announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare,…
Read More...

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) and Wacker Biotech, a contract development and…
Read More...

Nura Bio Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases,…
Read More...

Orbis Medicines, a leader in oral macrocycle drug discovery, announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the…
Read More...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a new drug application (NDA) for Blenrep (belantamab mafodotin) in combination with…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people…
Read More...

Zentalis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental…
Read More...

Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its…
Read More...

MaxCyte, Inc.,, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation…
Read More...

SOPHiA GENETICS, a cloud-native healthcare technology company and a global leader in data-driven medicine, announced a new milestone in the global introduction of the liquid biopsy test…
Read More...